Allegro receives US patent for integrin peptide therapy Luminate

Allegro announced a U.S. patent was issued for Luminate for “composition of matter” and “methods of use in the treatment of various ophthalmic disorders, neovascular conditions and tumors.”

This is the first U.S. patent Allegro has received, the announcement said.

Through anti-angiogenesis and vitreolysis, the integrin peptide therapy inhibits new blood vessel formation, reduces vascular leakage and accelerates liquefaction of the vitreous, according to the announcement.

Multiple phase 2 studies are underway in the U.S., where the investigational drug is not approved by the FDA for commercial sale.